Is Resection the Only Choice for the Treatment of Bilobar Colorectal Cancer Metastases?

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter A. Chiappa
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors A. Chiappa1, E. Bertani2, A. Zbar3, F. Luca4, G. Zampino Maria5, N. Fazio6, S. Ravenda Paola7, M. Venturino2, F. Orsi8, C. Ferrari9, I. Monsellato10, R. Biffi6
  • 1University of Milan -European Institute of Oncology, Milan, Italy, /
  • 2European Institute of Oncology, Milan, Italy, /
  • 3Department of General Surgery and Transplantation, Tel Aviv, Israel, /
  • 4Unit of Surgical multidisciplinary Techniques - European Institute of Oncology, Milan, Italy, /
  • 5VD Unità di Cure Mediche, Istituto Europeo Oncologico, Milano, Italy, /
  • 6European Institute of Oncology, Milano, Italy, /
  • 7Gastrointestinal and Neuroendocrine Tumour Unit - European Institute on Oncology, Milan, Italy, /
  • 8Division of Interventional Radiology - European Institute of Oncology, Milan, Italy, /
  • 9University of Milan, Milan, Italy, /
  • 10Division of Digestive Tract Surgery, Milan, Italy, /

Abstract

Traditionally multiple bilobar colorectal liver metastases (CRLM) were not considered suitable for radical resection. Only 25% of patients presenting with CRLM are amenable to surgery. We sought to determine the efficacy of combined resection and ablation for CRLM.